Back

Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy

12 May 2024 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 7 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Pietro Ameri

University of Genoa, Genova (Italy)

7 More presentations in this session

Presentation thumbnail
A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.
Doctor R. Mathur (Jodhpur, IN)
Abstract Slides Video
Presentation thumbnail
Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Diuresis efficacy in ambulatory congested heart failure patients: Intra -patient comparison of three diuretic regimens (DEA-HF)
Doctor A. Abbo (Haifa, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 7

The Event

Event poster

Heart Failure 2024

12 May 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
thumbnail
Congress Presentation
EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis
thumbnail
Congress Presentation
Dapagliflozin for heart failure with reduced ejection fraction: early experience of treatment adherence and impact on patient-reported outcomes in EVOLUTION HF, a multinational, observational study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources